P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.

Any treatment ( p < 0.001), surgery ( p < 0.001), chemotherapy ( p = 0.03) and adjuvant chemotherapy ( p < 0.001) was associated with improved survival. Despite the fact that the primary tumour origin did not reach statistical significance, there was a tendency for differences between the groups: Pancreatic primaries and CUPs had a median survival of 9 (5.1–12.9) and 6 (4.1–7.9) months, respectively, compared to upper and lower GI primaries with a median survival of 13 (10.0–16.0) and 12 (5.5–18.5) months, respectively.

also in 111,027 other papers